IFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Items recommended by the World Health Assembly and the Executive Board
IFPMA welcomes the opportunity to make this statement and to share our Covid-19 Lessons Learned, which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility must be preserved to ensure our collective ability to fight against unknown diseases.
The most important lesson of the report is that we must redouble collective efforts to achieve health equity, while ensuring health systems and delivery infrastructure are strengthened.
These learnings have resulted in industry tabling the Berlin Declaration, which proposes to create a collaborative solution for more equitable rollout of vaccines, treatments, and diagnostics for future pandemics.
In concrete terms, industry commits to setting aside doses specifically for poorer countries at the outset of a future pandemic.
A prerequisite for the declaration to succeed is to ensure that health systems in lower-income countries are better prepared to absorb and deliver vaccines and treatments, and for high income countries to provide the necessary political and financial support.
As discussions continue on how to strengthen health emergency preparedness, we must bear in mind that any future global health architecture must acknowledge a multistakeholder structure, including industry, public agencies, multilateral organizations, financial institutions, governments, and philanthropic organizations.
This is the only viable solution to managing pandemic crises in the region and beyond.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
Applying Lessons Learned from COVID-19 to Create a Healthier, Safer, More Equitable World
This report identifies 10 insights the biopharmaceutical industry has gathered so far as the world moves into the third year of the COVID-19 pandemic.
Read more
Berlin Declaration: Biopharmaceutical Industry Vision for Equitable Access in Pandemics
The innovative biopharmaceutical industry, having developed COVID-19 vaccines and treatments at record speed and in historic quantities, proposes to create a collaborative solution for more equitable rollout of vaccines, treatments and diagnostics for future pandemics. In particular, the innovative biopharmaceutical industry is willing to reserve an allocation of real-time production of vaccines, treatments and diagnostics...
Read moreIFPMA statement at the 73rd session of the WHO Regional Committee for Western Pacific: Noncommunicable disease prevention and control
IFPMA appreciates the opportunity to make this statement. The ongoing fight against COVID-19 has shown that those with chronic conditions and co-morbidities are often the most vulnerable and have suffered the most throughout the pandemic.
Read more